Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is among the top gainers of the stock market today, skyrocketing 2.48% or (0.71 points) to $29.3 from its previous close of $28.59. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 338472 contracts so far this session. AIMT shares had a relatively better volume day versus average trading capacity of 1.09 million shares, but with a 46.33 million float and a 2.8% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for AIMT stock indicates that the average analyst price target is $48.3 per share. This means the stock has a potential increase of 64.85% from where the AIMT share price has been trading recently which is between $27.6381 and $28.71. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $30. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $79.
During the recent trading session for Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the company witnessed their stock rise $1.86 over a week and surge $0.23 from the price 20 days ago. When compared to their established 52-week high of $29.68, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 08/11/19. The recent low of $16.95 stood for a -1.28% since 11/07/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of -0.06 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for AIMT is set at $47.5, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Aimmune Therapeutics, Inc., the two-week RSI stands at 64.29. This figure suggests that AIMT stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current AIMT readings is similarly very revealing as it has a stochastic reading of 85.76% at this stage. This figure means that AIMT share price today is being oversold.
Technical chart claims that Aimmune Therapeutics, Inc. (AIMT) would settle between $28.99/share to $29.38/share level. However, if the stock price goes below the $27.92 mark, then the market for Aimmune Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $27.24 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.71. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at ROTH Capital, assumed coverage of AIMT assigning Buy rating, according to their opinion released on July 12. Credit Suisse, analysts launched coverage of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) stock with a Outperform recommendation, according to their flash note issued to investors on May 21. Analysts at Goldman, made their first call for the equity with a Neutral recommendation, according to a research note that dated back to December 13.
AIMT equity has an average rating of 2.1, with the figure leaning towards a bullish end. 10 analysts who tracked the company were contacted by Reuters. Amongst them, 2 rated the stock as a hold while the remaining 8 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 8 analysts rated Aimmune Therapeutics, Inc. (NASDAQ:AIMT) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.